MindMed Becomes First Psychedelic Pharmaceutical Pure-Play

MindMed 成为第一个纯精神病药物

2020-03-03 23:40:34 CFN Media Group

本文共743个字,阅读需2分钟

Mind Medicine Inc. became the first psychedelic pharmaceutical company to go public on March 3, 2020. After raising $24.2 million in a pre-public funding round, the company went public on the NEO Stock Exchange, which has become a popular exchange among cannabis companies. “Today marks a significant step forward in our ability to access further institutional capital to fund our ground-breaking clinical trials and mission to build the most compelling pipeline of psychedelic inspired medicines,” said MindMed Co-Founder and Co-CEO JR Rahn. “NEO provided a clear, efficient path to go public on their institutional-grade main-board stock exchange. Psychedelic medicines present an opportunity to address large societal problems, like the opioid crisis, and a public listing of MindMed could help accelerate the path to a cure.” Currently, MindMed is gearing up for a Phase II clinical trial of 18-MC, a non-hallucinogenic drug candidate based on the psychedelic substance ibogaine. The company is also pursuing a Phase II macrodosing clinical trials or adult ADHD using LSD micro-dosing, which is expects to begin later this year. MindMed gained notoriety among cannabis investors after former Canopy Growth CEO Bruce Linton participated in a financing round alongside Kevin O’Leary — who is best known as Mr. Wonderful on ABC’s Shark Tank. With the IPO, any retail investors can buy and sell shares through the NEO stock exchange via discount and full service brokers. This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Mind Medicine Inc .于2020年3月3日成为首家上市的迷幻药公司。该公司在上市前融资2,420万美元后,在 NEO 证券交易所上市,该交易所已成为大麻公司之间的热门交易所。 Mindma 联合创始人兼联合首席执行官 JR Rahn 表示:“今天标志着我们获得更多机构资本的能力向前迈出了重要一步,为我们开创性的临床试验提供资金,并致力于打造最引人注目的迷幻药渠道。” “ NEO 提供了在机构级主板证券交易所上市的清晰、高效的途径。精神类药物提供了一个解决大型社会问题的机会,比如阿片类药物危机, MindMed 的公开上市可以帮助加速治疗的进程。” 目前, Mindm 正在准备进行18-MC 的 II 期临床试验,这是一种非致幻性药物候选药物,基于精神药物 ibogaine 。该公司还正在进行 II 期大剂量临床试验或成人 ADHD 使用 LSD 微剂量,预计将于今年晚些时候开始。 MindMed 在大麻投资者中声名狼藉,此前 Canopy Growth 前首席执行官布鲁斯·林顿( Bruce Linton )与凯文·奥利里( Kevin O ’ Leary )一起参与了一轮融资,凯文·奥利里( Kevin O ’ Leary )在 ABC 的“沙坑”( Shark Tank )上以 Wonderful 闻名。通过 IPO ,任何散户投资者都可以通过折价和全套服务的经纪商,通过 NEO 证券交易所买卖股票。 这篇文章由 CFN Enterprises Inc .( OTCQB : CNFN )出版, CFN Media 是该行业领先的代理机构和数字金融媒体网络,致力于新兴的 CBD 和合法大麻行业。致电+1(833)420-CNFN 获取更多信息。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文